FDA Orange Book · active-ingredient family
Degarelix acetate
Degarelix acetate is approved in 1 FDA application, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.
Reference-listed drug:FIRMAGON · NDA 022201
1
Brand (NDA)
0
Generics (ANDA)
9
Listed patents
0
Exclusivity periods
Brand (NDA) products · powder
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| FIRMAGONRLD×2 | FERRING | NDA 022201 | — | Dec 24, 2008 |
Listed patents (9)
| Patent | Expires | In | Type |
|---|---|---|---|
| 9579359 | Feb 10, 2029 | in 2 yr 8 mo | U-1978 |
| 10973870 | Feb 10, 2029 | in 2 yr 8 mo | U-1978 |
| 10729739 | Feb 10, 2029 | in 2 yr 8 mo | U-1978 |
| 12514898 | Feb 20, 2029 | in 2 yr 9 mo | U-1978 |
| 12533387 | Feb 20, 2029 | in 2 yr 9 mo | U-4417 |
| 10695398 | Apr 27, 2032 | in 5 yr 11 mo | U-1895 |
| 9415085 | Apr 27, 2032 | in 5 yr 11 mo | U-1895 |
| 11766468 | Apr 27, 2032 | in 5 yr 11 mo | U-1978 |
| 11826397 | Apr 27, 2032 | in 5 yr 11 mo | U-1978 |
Degarelix acetate — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
